Clinical Trials Sponsored by PDL BioPharma, Inc.

Total 335 results

Facet Biotech
PDL BioPharma, Inc.

Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

France, Belgium, United States, Israel, Australia, Germany, Netherlands, Austria, Canada, Czech Republic, Ukraine, Norway, Hungary, Slovakia
Facet Biotech
PDL BioPharma, Inc.

Terminated

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Ulcerative Colitis

Belgium, France, United States, Italy, Canada, Czech Republic, Norway, Israel, Austria, Croatia, Australia, Hungary, Ukraine, Netherlands, Germany
Facet Biotech
PDL BioPharma, Inc.

Withdrawn

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Intravenous Steroid-Refractory Ulcerative Colitis
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

Crohn's Disease

United States
PDL BioPharma, Inc.

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases

United States
PDL BioPharma, Inc.

Terminated

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States
Facet Biotech
PDL BioPharma, Inc.

Completed

Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

Severe Ulcerative Colitis

United States
Facet Biotech
PDL BioPharma, Inc.

Completed

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

Crohn's Disease

United States
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
PDL BioPharma, Inc.

Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

Belgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
OSF Healthcare System
PDL BioPharma, Inc.

Unknown

IV Double and Triple Concentrated Nicardipine for Stroke and ICH

Hypertension

United States
PDL BioPharma, Inc.

Unknown

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
KDL Inc.

Completed

A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia

Japan
KDL Inc.

Unknown

A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis

End Stage Renal Disease | Hyperphosphatemia

Australia
BioPharmX, Inc.

Completed

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

Moderate to Severe Papulopustular Rosacea

United States
BioPharmX, Inc.

Completed

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris (OPAL)

Acne Vulgaris

United States
BioPharmX, Inc.

Completed

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

Acne Vulgaris

United States
BioPharmX, Inc.

Unknown

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea (PRISM)

Papulopustular Rosacea

United States
BioPharmX, Inc.

Completed

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline

Acne

United States
HC Biopharma Inc.

Recruiting

A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Acrotech Biopharma Inc.

Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO)

Peripheral T Cell Lymphoma

United States
Sutro Biopharma, Inc.

Recruiting

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Ovarian Carcinoma | Endometrioid Adenocarcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States, Spain
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma

United States
Landos Biopharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Ulcerative Colitis

United States, Ukraine
Sutro Biopharma, Inc.

Active, not recruiting

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Indolent Lymphoma | B Cells--Tumors

United States
GT Biopharma, Inc.

Terminated

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Acute Myelogenous Leukemia | Systemic Mastocytosis | Mast Cell Leukemia | High-risk Myelodysplastic Syndromes

United States
Sumitovant Biopharma, Inc.

Completed

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Bacterial Infections

United States
Civi Biopharma, Inc.

Completed

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Hypercholesterolemia

United States
ReveraGen BioPharma, Inc.

Withdrawn

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Pediatric Ulcerative Colitis
Therapure Biopharma Inc

Unknown

Study of PlasmaCap IG in Adults and Children With PIDD

Primary Immune Deficiency Diseases (PIDD)

United States, Canada
Acrotech Biopharma Inc.

Withdrawn

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Non-Small Cell Lung Cancer
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

B-cell Lymphoma | Hodgkin's Lymphoma | Relapsed or Refractory Lymphoproliferative Malignancies | Peripheral T-cell Lymphoma | Waldenstrom's Macroglobulinemia

United States
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

Breast Cancer | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Human Mammary Carcinoma

France, United States, Czechia, Hungary
Alios Biopharma Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Chronic Hepatitis C

New Zealand, Moldova, Republic of, Mauritius, United Kingdom
Alios Biopharma Inc.

Completed

A Study of ALS-008176 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

United States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
Alios Biopharma Inc.

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Influenza in Humans

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

Australia, Singapore, United States, New Zealand, Taiwan
Alios Biopharma Inc.

Completed

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Influenza

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
S1 Biopharma, Inc.

Completed

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety (PURPLE)

Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined) | Sexual Interest/Arousal Disorder (DSM-5 Defined)

United States
ARCA Biopharma, Inc.

Completed

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

Catheters, Indwelling

United States
Ambrilia Biopharma, Inc.

Completed

Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Serbia, Ukraine, Romania, Slovakia
ARCA Biopharma, Inc.

Suspended

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

Colon Cancer

United States
ARCA Biopharma, Inc.

Terminated

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Acute Ischemic Stroke

United States, Canada
ARCA Biopharma, Inc.

Completed

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

Arterial Occlusive Diseases

United States
HC Biopharma Inc.

Recruiting

A Study of HC006 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
AiViva BioPharma, Inc.

Recruiting

Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
Vitro Biopharma Inc.

Not yet recruiting

Safety & Efficacy of AlloRx SC® in PTHS Patients

Pitt Hopkins Syndrome
Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan

Clinical Trials Sponsored by PDL BioPharma, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations